Image 1
Chemical structure of trospium chloride, showing the molecular arrangement of its atoms and bonds as depicted in the image.*
Trospium Chloride Capsule, Extended Release
Product Images NDC 0591-3636
7 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 0591-3636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
A line graph depicting the plasma concentration (mg/mL) over time (hours post-dose) for Trospium Chloride extended-release capsules 60 mg. The graph shows concentration levels rising to a peak near 4 hours post-dose and gradually declining up to 24 hours.*
Image 3
A line graph comparing the average change over weeks of treatment between placebo and Trospium chloride extended-release capsules (60 mg) groups. The x-axis shows weeks (0, 1, 4, 12), and the y-axis shows average change with standard error bars. The Trospium group shows a greater decrease over time compared to placebo, with p-values indicating statistical significance at points 1, 4, and 12 weeks.*
Image 4
A line graph comparing average percentage change over 12 weeks between placebo and Trospium chloride extended-release capsules groups. The x-axis represents the week of treatment (0, 1, 4, 12), and the y-axis shows the average percentage change with standard error bars. Significant p-values are noted at weeks 1, 4, and 12 for the Trospium chloride group versus placebo.*
Image 5
A line graph comparing average change over 12 weeks between placebo and Trospium chloride extended-release capsules. The x-axis represents weeks of treatment (0, 1, 4, 12), and the y-axis shows average change with standard error. The graph includes sample sizes for both groups (N=267) and p-values at weeks 1, 4, and 12, indicating statistical differences.*
Image 6
A line graph comparing average changes over weeks of treatment between placebo and Trospium chloride extended-release capsules groups. The graph shows data points at weeks 0, 1, 4, and 12, with error bars representing standard error, indicating decreasing values over time, with statistical significance noted at weeks 1, 4, and 12.*
Image 7
Label of Trospium Chloride 60 mg extended-release capsules by Actavis Pharma, Inc. The label shows a red and gray capsule marked WPI 3636, indicates 30 capsules in the container, and includes dispensing, storage, and manufacturer information along with the product NDC 0591-3636-30 barcode.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
